Protective effects of oleanolic acid oligoglycosides on ethanol- or indomethacin-induced gastric mucosal lesions in rats

被引:51
作者
Matsuda, H [1 ]
Li, YH [1 ]
Murakami, T [1 ]
Yamahara, J [1 ]
Yoshikawa, M [1 ]
机构
[1] Kyoto Pharmaceut Univ, Yamashima Ku, Kyoto 6078414, Japan
关键词
oleanolic acid oligoglycoside; oleanolic acid 3-O-monodesmoside; momordin Ic; ethanol-induced gastric lesion; indomethacin-induced gastric lesion; gastroprotection;
D O I
10.1016/S0024-3205(98)00426-3
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
We examined the effects of various oleanolic acid oligoglycosides obtained from traditional herbs on ethanol- or indomethacin-induced gastric mucosal lesions in rats and on gastric secretion in pylorus-ligated rats. Test samples were given orally to fasted rats 1 h before absolute ethanol (1.5 ml/rat, p.o.) or indomethacin (30 mg/kg, s.c.) treatment, or ligation of the pylorus. Oleanolic acid 3-O-monodesmosides [oleanolic acid 3-O-glucuronide (1, 20-50 mg/kg), momordin Ic (2, 5-50 mg/kg), and 28-O-deglucosyl-chikusetsusaponins IV (5, 10-50 mg/kg) and V (7, 10-50 mg/kg)] were found to show protective effects on ethanol-induced gastric mucosal lesions, whereas oleanolic acid 3,28-O-bisdesmosides [momordin IIc (3), chikusetsusaponins IV (4) and V (6)], oleanolic acid 28-O-monodesmoside [compound O (8)], and their common aglycon [oleanolic acid (9)] showed no such effects. Oleanolic acid 3-O-monodesmosides (1, 2, and 5) also showed protective effects on indomethacin-induced gastric mucosal lesions. 28-O-Deglucosyl-chikusetsusaponin V (7) did not inhibit the indomethacin-induced lesions, while chikusetsusaponins V (6, 50 mg/kg) had the gastroprotective effect. These active saponins (1, 2, 4-7, 10-50 mg/kg) did not decrease the gastric secretion by oral administration in pylorus-ligated rats. (C) 1998 Elsevier Science Inc.
引用
收藏
页码:PL245 / PL250
页数:6
相关论文
共 24 条
[1]  
ADAMI E, 1964, ARCH INT PHARMACOD T, V147, P113
[2]   The estimation of pepsin, trypsin, papain, and cathepsin with hemoglobin [J].
Anson, ML .
JOURNAL OF GENERAL PHYSIOLOGY, 1938, 22 (01) :79-89
[3]   GASTRIC ECL-CELL HYPERPLASIA AND CARCINOIDS IN RODENTS FOLLOWING CHRONIC ADMINISTRATION OF H2-ANTAGONISTS SK-AND-F-93479 AND OXMETIDINE AND OMEPRAZOLE [J].
BETTON, GR ;
DORMER, CS ;
WELLS, T ;
PERT, P ;
PRICE, CA ;
BUCKLEY, P .
TOXICOLOGIC PATHOLOGY, 1988, 16 (02) :288-298
[4]   A REVIEW OF THE EFFECTS OF LONG-TERM ACID INHIBITION IN ANIMALS [J].
CARLSSON, E .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1989, 24 :19-26
[5]   REBOUND NOCTURNAL HYPERSECRETION AFTER 4 WEEKS TREATMENT WITH AN H-2-RECEPTOR ANTAGONIST [J].
FULLARTON, GM ;
MCLAUCHLAN, G ;
MACDONALD, A ;
CREAN, GP ;
MCCOLL, KEL .
GUT, 1989, 30 (04) :449-454
[6]   EXPERIMENTAL GASTRIC-MUCOSAL INJURY - LABORATORY MODELS REVEAL MECHANISMS OF PATHOGENESIS AND NEW THERAPEUTIC STRATEGIES [J].
GLAVIN, GB ;
SZABO, S .
FASEB JOURNAL, 1992, 6 (03) :825-831
[7]  
KONTUREK SJ, 1983, GUT PEPTIDES ULCER, P411
[8]   LONG-TERM OMEPRAZOLE THERAPY IN PEPTIC-ULCER DISEASE - GASTRIN, ENDOCRINE CELL-GROWTH, AND GASTRITIS [J].
LAMBERTS, R ;
CREUTZFELDT, W ;
STRUBER, HG ;
BRUNNER, G ;
SOLCIA, E .
GASTROENTEROLOGY, 1993, 104 (05) :1356-1370
[9]   ESOPHAGEAL CANDIDIASIS AFTER OMEPRAZOLE THERAPY [J].
LARNER, AJ ;
LENDRUM, R .
GUT, 1992, 33 (06) :860-861
[10]   OMEPRAZOLE - THE 1ST PROTON PUMP INHIBITOR [J].
LINDBERG, P ;
BRANDSTROM, A ;
WALLMARK, B ;
MATTSSON, H ;
RIKNER, L ;
HOFFMANN, KJ .
MEDICINAL RESEARCH REVIEWS, 1990, 10 (01) :1-54